ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation.

Trial Profile

ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Gliclazide (Primary) ; Perindopril/indapamide (Primary) ; Antihyperglycaemics
  • Indications Cardiovascular disorders; Diabetic angiopathies; Diabetic complications; Diabetic nephropathies; Diabetic retinopathy; Hypertension; Proteinuria; Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms ADVANCE
  • Sponsors Servier
  • Most Recent Events

    • 01 Sep 2016 Results of post-hoc analysis (n=11140) published in the Diabetologia (2016).
    • 03 Aug 2012 Additional lead trial investigator and centre added as reported by ClinicalTrials.gov.
    • 07 Oct 2010 Hypoglycaemia and the risks of vascular events/death was published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top